<p>10x Genomics（纳斯达克代码：TXG - 获取免费报告）周四交易中股价下跌了 6.7%。该股最低交易价格为 16.40 美元，最后交易价格为 16.3510 美元。交易期间共成交 462,460 股，较平均交易量 3,185,433 股下降了 85%。该股此前收盘价为 17.53 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>战略买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
<p>多位研究分析师最近对 TXG 股票发表了看法。Weiss Ratings 在周一的研究报告中重新发布了对 10x Genomics 的 “卖出（d-）” 评级。巴克莱将 10x Genomics 的目标价格从 15.00 美元上调至 17.00 美元，并在 11 月 7 日的研究报告中给予该公司 “增持” 评级。华尔街 Zen 在 11 月 15 日的研究报告中将 10x Genomics 的评级从 “买入” 下调至 “持有”。花旗集团在周四的研究报告中重申了对 10x Genomics 的 “中性” 评级。最后，瑞银集团在 11 月 7 日的报告中将 10x Genomics 的目标价格从 13.00 美元上调至 14.00 美元，并给予该公司 “中性” 评级。四位投资分析师对该股给予 “买入” 评级，十位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “持有”，平均目标价格为 15.12 美元。</p>
<p><strong>查看我们关于 TXG 的最新报告</strong></p>
<h2>10x Genomics 股票表现</h2>
<p>该公司的 50 日移动平均线为 14.93 美元，200 日移动平均线为 13.19 美元。该公司的市值为 21 亿美元，市盈率为-26.76，贝塔值为 2.15。</p>
<p>10x Genomics（纳斯达克代码：TXG - 获取免费报告）于 11 月 6 日（周四）发布了季度财报。该公司报告本季度每股收益为（0.22 美元），超出市场共识预期的（0.27 美元）0.05 美元。10x Genomics 的净利润率为-11.89%，股本回报率为-11.50%。该公司本季度的收入为 1.49 亿美元，而分析师预期为 1.425 亿美元。去年同期，该公司每股收益为（0.30 美元）。该公司的季度收入较去年同期下降了 1.7%。整体来看，分析师预计 10x Genomics 在本财年将发布-1.43 的每股收益。</p>
<h2>内部人士下注</h2>
<p>在相关消息中，首席财务官 Adam Taich 于 11 月 24 日（周一）出售了 11,888 股该股票，交易价格为 19.00 美元，总交易额为 225,872.00 美元。交易完成后，首席财务官直接持有该公司 297,385 股，价值约为 5,650,315 美元。此交易代表其持股比例下降了 3.84%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，内部人士 Benjamin J. Hindson 于 11 月 24 日（周一）出售了 8,283 股 10x Genomics 股票，交易价格为 19.00 美元，总价值为 157,377.00 美元。交易完成后，该内部人士直接持有 432,605 股，价值约为 8,219,495 美元。这代表其持股比例下降了 1.88%。有关此交易的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士共出售了价值 635,208 美元的 33,432 股公司股票。公司内部人士持有公司股票的 9.39%。</p>
<h2>10x Genomics 的机构交易</h2>
<p>多位大型投资者最近增加或减少了对该公司的持股。瑞银资产管理公司（UBS AM）在第一季度将其在 10x Genomics 的持股比例提高了 235.6%。瑞银资产管理公司现在拥有 7,103,768 股该公司股票，价值 62,016,000 美元，此前在此期间又购买了 4,987,195 股。千禧管理公司（Millennium Management LLC）在第一季度将其在 10x Genomics 的持股比例提高了 434.5%。千禧管理公司现在拥有 5,377,492 股该公司股票，价值 46,946,000 美元，此前在上个季度又收购了 4,371,327 股。AQR 资本管理公司（AQR Capital Management LLC）在第二季度将其在 10x Genomics 的持股比例提高了 241.3%。AQR 资本管理公司现在拥有 4,137,801 股该公司股票，价值 47,916,000 美元，此前在上个季度又收购了 2,925,372 股。威灵顿管理集团（Wellington Management Group LLP）在第三季度将其在 10x Genomics 的持股比例提高了 126.6%。威灵顿管理集团现在拥有 4,285,628 股该公司股票，价值 50,099,000 美元，此前在此期间又收购了 2,394,355 股。最后，Quantinno 资本管理公司（Quantinno Capital Management LP）在第二季度将其在 10x Genomics 的持股比例提高了 207.2%。Quantinno 资本管理公司现在拥有 2,233,526 股该公司股票，价值 25,864,000 美元，此前在上个季度又购买了 1,506,530 股。机构投资者和对冲基金持有该公司 84.68% 的股票。</p>
<h2>10x Genomics 公司简介</h2>
<p>（获取免费报告）</p>
<p>10x Genomics, Inc 是一家生命科学技术公司，开发和销售用于分析生物系统的仪器、耗材和软件，业务覆盖美洲、欧洲、中东、非洲、中国和亚太地区。该公司提供铬、铬连接和铬控制仪器、微流控芯片、载玻片、试剂和其他耗材产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 10x Genomics</li>
<li>安静期到期的解释</li>
<li>量子舰队：投资新的量子标准</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>AST SpaceMobile 为下周的 BlueBird 6 发射做好准备</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>人工智能与量子技术的下一个赢家：2026 年值得关注的三只小盘股</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 10x Genomics 吗？</h2>
<p>在你考虑 10x Genomics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 10x Genomics 并不在名单上。</p>
<p>虽然 10x Genomics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>10X Genomics（纳斯达克代码：TXG）股价下跌 6.7%，至 16.3510 美元，交易量为 462,460 股，较平均水平下降 85%。分析师的评级意见不一：Weiss Ratings - 卖出，巴克莱 - 超配，华尔街禅 - 持有，花旗集团和瑞银 - 中性。该公司报告的第三季度收益好于预期，但净利润率和股本回报率均为负值。内部人士近期出售了股份。机构投资者显著增加了他们的持股比例</p>

<p>10x Genomics (NASDAQ:TXG - Get Free Report)'s share price fell 6.7% during trading on Thursday . The stock traded as low as $16.40 and last traded at $16.3510. 462,460 shares traded hands during trading, a decline of 85% from the average session volume of 3,185,433 shares. The stock had previously closed at $17.53.</p>
<div class="lb-trans"><p>10x Genomics（纳斯达克代码：TXG - 获取免费报告）周四交易中股价下跌了 6.7%。该股最低交易价格为 16.40 美元，最后交易价格为 16.3510 美元。交易期间共成交 462,460 股，较平均交易量 3,185,433 股下降了 85%。该股此前收盘价为 17.53 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li>
</ul>
<div class="lb-trans"><ul>
<li>战略买入点亮这只生物科技股票：是时候投资了吗？</li>
</ul>
</div><p>A number of research analysts have recently weighed in on TXG shares. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of 10x Genomics in a research note on Monday. Barclays increased their target price on 10x Genomics from $15.00 to $17.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, November 7th. Wall Street Zen lowered 10x Genomics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 15th. Citigroup reiterated a &#34;neutral&#34; rating on shares of 10x Genomics in a research report on Thursday. Finally, UBS Group boosted their price objective on shares of 10x Genomics from $13.00 to $14.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $15.12.</p>
<div class="lb-trans"><p>多位研究分析师最近对 TXG 股票发表了看法。Weiss Ratings 在周一的研究报告中重新发布了对 10x Genomics 的 “卖出（d-）” 评级。巴克莱将 10x Genomics 的目标价格从 15.00 美元上调至 17.00 美元，并在 11 月 7 日的研究报告中给予该公司 “增持” 评级。华尔街 Zen 在 11 月 15 日的研究报告中将 10x Genomics 的评级从 “买入” 下调至 “持有”。花旗集团在周四的研究报告中重申了对 10x Genomics 的 “中性” 评级。最后，瑞银集团在 11 月 7 日的报告中将 10x Genomics 的目标价格从 13.00 美元上调至 14.00 美元，并给予该公司 “中性” 评级。四位投资分析师对该股给予 “买入” 评级，十位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股目前的共识评级为 “持有”，平均目标价格为 15.12 美元。</p>
</div><p><strong>Check Out Our Latest Report on TXG</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 TXG 的最新报告</strong></p>
</div><h2>10x Genomics Stock Performance</h2>
<div class="lb-trans"><h2>10x Genomics 股票表现</h2>
</div><p>The company has a 50-day moving average of $14.93 and a 200-day moving average of $13.19. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -26.76 and a beta of 2.15.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 14.93 美元，200 日移动平均线为 13.19 美元。该公司的市值为 21 亿美元，市盈率为-26.76，贝塔值为 2.15。</p>
</div><p>10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company had revenue of $149.00 million during the quarter, compared to analysts' expectations of $142.50 million. During the same quarter in the prior year, the company earned ($0.30) earnings per share. The business's quarterly revenue was down 1.7% compared to the same quarter last year. As a group, analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>10x Genomics（纳斯达克代码：TXG - 获取免费报告）于 11 月 6 日（周四）发布了季度财报。该公司报告本季度每股收益为（0.22 美元），超出市场共识预期的（0.27 美元）0.05 美元。10x Genomics 的净利润率为-11.89%，股本回报率为-11.50%。该公司本季度的收入为 1.49 亿美元，而分析师预期为 1.425 亿美元。去年同期，该公司每股收益为（0.30 美元）。该公司的季度收入较去年同期下降了 1.7%。整体来看，分析师预计 10x Genomics 在本财年将发布-1.43 的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, CFO Adam Taich sold 11,888 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $225,872.00. Following the completion of the transaction, the chief financial officer directly owned 297,385 shares in the company, valued at approximately $5,650,315. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 8,283 shares of 10x Genomics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $157,377.00. Following the completion of the sale, the insider directly owned 432,605 shares in the company, valued at approximately $8,219,495. This represents a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 33,432 shares of company stock worth $635,208. Corporate insiders own 9.39% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Adam Taich 于 11 月 24 日（周一）出售了 11,888 股该股票，交易价格为 19.00 美元，总交易额为 225,872.00 美元。交易完成后，首席财务官直接持有该公司 297,385 股，价值约为 5,650,315 美元。此交易代表其持股比例下降了 3.84%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，内部人士 Benjamin J. Hindson 于 11 月 24 日（周一）出售了 8,283 股 10x Genomics 股票，交易价格为 19.00 美元，总价值为 157,377.00 美元。交易完成后，该内部人士直接持有 432,605 股，价值约为 8,219,495 美元。这代表其持股比例下降了 1.88%。有关此交易的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士共出售了价值 635,208 美元的 33,432 股公司股票。公司内部人士持有公司股票的 9.39%。</p>
</div><h2>Institutional Trading of 10x Genomics</h2>
<div class="lb-trans"><h2>10x Genomics 的机构交易</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in 10x Genomics by 235.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock worth $62,016,000 after purchasing an additional 4,987,195 shares during the period. Millennium Management LLC lifted its position in 10x Genomics by 434.5% during the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company's stock worth $46,946,000 after acquiring an additional 4,371,327 shares during the last quarter. AQR Capital Management LLC lifted its position in 10x Genomics by 241.3% during the second quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company's stock worth $47,916,000 after acquiring an additional 2,925,372 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of 10x Genomics by 126.6% during the third quarter. Wellington Management Group LLP now owns 4,285,628 shares of the company's stock worth $50,099,000 after acquiring an additional 2,394,355 shares during the period. Finally, Quantinno Capital Management LP grew its position in shares of 10x Genomics by 207.2% in the second quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company's stock valued at $25,864,000 after purchasing an additional 1,506,530 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.</p>
<div class="lb-trans"><p>多位大型投资者最近增加或减少了对该公司的持股。瑞银资产管理公司（UBS AM）在第一季度将其在 10x Genomics 的持股比例提高了 235.6%。瑞银资产管理公司现在拥有 7,103,768 股该公司股票，价值 62,016,000 美元，此前在此期间又购买了 4,987,195 股。千禧管理公司（Millennium Management LLC）在第一季度将其在 10x Genomics 的持股比例提高了 434.5%。千禧管理公司现在拥有 5,377,492 股该公司股票，价值 46,946,000 美元，此前在上个季度又收购了 4,371,327 股。AQR 资本管理公司（AQR Capital Management LLC）在第二季度将其在 10x Genomics 的持股比例提高了 241.3%。AQR 资本管理公司现在拥有 4,137,801 股该公司股票，价值 47,916,000 美元，此前在上个季度又收购了 2,925,372 股。威灵顿管理集团（Wellington Management Group LLP）在第三季度将其在 10x Genomics 的持股比例提高了 126.6%。威灵顿管理集团现在拥有 4,285,628 股该公司股票，价值 50,099,000 美元，此前在此期间又收购了 2,394,355 股。最后，Quantinno 资本管理公司（Quantinno Capital Management LP）在第二季度将其在 10x Genomics 的持股比例提高了 207.2%。Quantinno 资本管理公司现在拥有 2,233,526 股该公司股票，价值 25,864,000 美元，此前在上个季度又购买了 1,506,530 股。机构投资者和对冲基金持有该公司 84.68% 的股票。</p>
</div><h2>10x Genomics Company Profile</h2>
<div class="lb-trans"><h2>10x Genomics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.</p>
<div class="lb-trans"><p>10x Genomics, Inc 是一家生命科学技术公司，开发和销售用于分析生物系统的仪器、耗材和软件，业务覆盖美洲、欧洲、中东、非洲、中国和亚太地区。该公司提供铬、铬连接和铬控制仪器、微流控芯片、载玻片、试剂和其他耗材产品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than 10x Genomics</li>
<li>Quiet Period Expirations Explained</li>
<li>The Quantum Fleet: Investing in the New Quantum Standard</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>AST SpaceMobile Gears Up for Its BlueBird 6 Launch Next Week</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>AI &amp; Quantum's Next Big Winners: 3 Small-Cap Stocks to Watch in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 10x Genomics</li>
<li>安静期到期的解释</li>
<li>量子舰队：投资新的量子标准</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>AST SpaceMobile 为下周的 BlueBird 6 发射做好准备</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>人工智能与量子技术的下一个赢家：2026 年值得关注的三只小盘股</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in 10x Genomics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 10x Genomics 吗？</h2>
</div><p>Before you consider 10x Genomics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 10x Genomics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 10x Genomics 并不在名单上。</p>
</div><p>While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 10x Genomics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

10x Genomics（NASDAQ:TXG）股价下跌 6.7% - 现在是卖出的时候吗？